Trefentanil
 | |
| Systematic (IUPAC) name | |
|---|---|
|
N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-phenylpiperidin-4-yl}-N-(2-fluorophenyl)propanamide | |
| Identifiers | |
| CAS Number |
120656-93-1  |
| ATC code | none |
| PubChem | CID 60728 |
| ChemSpider |
54732  |
| UNII |
36QM58LVGU |
| ChEMBL |
CHEMBL84617 |
| Chemical data | |
| Formula | C25H31FN6O2 |
| Molar mass | 466.551 g/mol |
| |
| |
| (what is this?) (verify) | |
Trefentanil (A-3665) is an opioid analgesic that is an analogue of fentanyl and was developed in 1992.[1]
Trefentanil is most similar to short-acting fentanyl analogues such as alfentanil. In comparative studies, trefentanil was slightly more potent and shorter acting than alfentanil as an analgesic,[2] but induced significantly more severe respiratory depression.[3] For this reason trefentanil has not been adopted for clinical use, although it is still used in research.
Trefentanil has very similar effects to alfentanil, much like those of fentanyl itself but more potent and shorter lasting. Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.[4] The risk of respiratory depression is especially high with potent fentanyl analogues such as alfentanil and trefentanil, and these drugs pose a significant risk of death if used outside of a hospital setting with appropriate artificial breathing apparatus available.
References
- ↑ Cambareri JJ, Afifi MS, Glass PS, Esposito BF, Camporesi EM. A-3665, a new short-acting opioid: a comparison with alfentanil. Anesthesia and Analgesia. 1993 Apr;76(4):812-6.
- ↑ Lemmens HJ, Dyck JB, Shafer SL, Stanski DR. Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. Clinical Pharmacology and Therapeutics. 1994 Sep;56(3):261-71.
- ↑ Cambareri JJ, Afifi MS, Glass PS, Esposito BF, Camporesi EM. A-3665, a new short-acting opioid: a comparison with alfentanil. Anesthesia and Analgesia. 1993 Apr;76(4):812-6.
- ↑ Jane Mounteney, Isabelle Giraudon, Gleb Denissov, Paul Griffiths (July 2015). "Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe.". The international journal of drug policy. 26 (7): 626–631. doi:10.1016/j.drugpo.2015.04.003. PMID 25976511.